patients who are over 18 represent less than only 30% of the total patient. This company is loosing in the hep C war. Today news was supposed to be a bad news; however, the market is so strong; therefore, it can hold well today. A bad market day would make it looking for 61 again.
it's about 700 patients. but this is small fry. the real data will be the combo studies in early 2014.....that will jump the potential patient pool by thousands (tens of) and the revenue by bilions. yesterday's news is not significant from a revenue standpoint....maybe $200-250m.....sounds litke s lot but it's not what vertex longs are waiting for.